Transforming growth factor beta 2 messenger RNA (TGFB2 mRNA)

Transforming growth factor beta 2 (TGFβ2) mRNA is the genetic template for the synthesis of the TGFβ2 cytokine, a potent regulator of various cellular processes including growth, differentiation, and immune suppression (Schlingensiepen et al., 2006). In many advanced cancers, such as high-grade gliomas and pancreatic adenocarcinoma, TGFβ2 is significantly upregulated, serving as a key factor in tumor-mediated immunosuppression, metastasis, and angiogenesis (Bogdahn et al., 2011). Trabedersen (also known as AP 12009) is a synthetic antisense phosphorothioate oligodeoxynucleotide specifically designed to hybridize with the human TGFβ2 mRNA (Vallières, 2009). By binding to the mRNA, trabedersen inhibits the translation of the TGFβ2 protein, thereby reducing its pathological effects in the tumor microenvironment. This therapeutic strategy is designed to restore the patient's anti-tumor immune response and inhibit the aggressive growth characteristics of TGFβ2-secreting tumors (Isarna Therapeutics, 2024). Clinical trials have explored the use of trabedersen in patients with recurrent or refractory high-grade glioma, demonstrating its potential to improve survival by targeting the underlying molecular drivers of the disease (Bogdahn et al., 2011).

Other names

TGF-beta-2 mRNATGFB2 transcriptAP 12009 targetTransforming growth factor beta-2 mRNA

Antisense oligonucleotide-mediated inhibition of protein translation by sequence-specific binding to mRNA (Schlingensiepen et al., 2006)